Wegovy for Cardiovascular Risk Reduction Wegovy (semaglutide) gained FDA approval for reducing cardiovascular death, heart attack, and stroke risk in adults with established cardiovascular disease who are overweight or obese
Take a look at our Micro-Infusion safety protocols and treatment instructions
Additionally, both oral medication kits and compounded GLP-1 injections are eligible for HSA or FSA reimbursement so if you have a health savings account (HSA) or flexible spending account (FSA), it might help save 30% on average.**** Compounded products are not approved nor evaluated for safety, effectiveness, or quality by FDA
In a double-blind study with a placebo group, chronic insomniac patients administered with a DSIP analogue experienced a reduction in sleep latency by an average of 22 minutes, suggesting its potential as a therapeutic agent for severe chronic insomnia patients (Anderer & Saletu, 1991)
Always inform your healthcare provider of any other medications you're taking to avoid potential interactions
In early clinical trials, Amycretin has been associated with mild to moderate gastrointestinal side effects, primarily nausea and vomiting